0JSY Stock Chart & Stats
$311.60
-$35.18(-11.31%)
At close: 4:00 PM EDT
$311.60
-$35.18(-11.31%)
Day’s Range― - ―
52-Week Range$245.87 - $326.00
Previous CloseN/A
Volume1.00
Average Volume (3M)175.00
Market Cap
$25.80B
Enterprise Value$29.60K
Total Cash (Recent Filing)$141.80M
Total Debt (Recent Filing)$6.77B
Price to Earnings (P/E)26.6
Beta0.64
Next Earnings
Oct 22, 2026EPS Estimate
4.65Next Dividend Ex-DateN/A
Dividend Yield0.89%
Share Statistics
EPS (TTM)12.17
Shares Outstanding81,100,000
10 Day Avg. Volume258
30 Day Avg. Volume175
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)2.42
Price to Sales (P/S)1.50
P/FCF Ratio17.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$338.27Price Target Upside8.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)18.31
Revenue Forecast (FY)$14.74B
Bulls Say, Bears Say
Bulls Say
Revenue And Margin ExpansionBroad-based revenue growth alongside margin expansion indicates improving operating leverage across Diagnostics and Drug Development. If sustained, stronger profitability can support earnings growth and increase Labcorp’s capacity to reinvest in technology, testing, and customer relationships.
Biopharma Backlog VisibilityThe sizable backlog and book-to-bill above one provide meaningful forward revenue visibility for Biopharma Laboratory Services. This supports planning, utilization, and customer retention while reducing reliance on near-term contract wins to sustain segment growth.
Molecular Diagnostics ExpansionFDA-approved companion diagnostics expand Labcorp’s role in precision medicine and can deepen relationships with hospitals, laboratories, and pharmaceutical developers. The kit-based format may broaden adoption while creating opportunities for follow-on testing and clinical research.
Bears Say
High Absolute Leverage And Low CashMeaningful debt relative to the company’s cash balance reduces financial flexibility if diagnostics reimbursement weakens or biopharma activity slows. Although debt is described as manageable, refinancing needs and interest obligations could constrain acquisitions, investment, or shareholder returns.
Weaker Cash ConversionLabcorp remains cash generative, but the recent free-cash-flow decline and less-than-one-times conversion of earnings into operating cash indicate less consistent cash quality. Persistent working-capital or capital-spending demands could limit deleveraging and reduce funding flexibility.
PAMA Regulatory UncertaintyPotential PAMA implementation remains a structural reimbursement risk for Diagnostics. Changes to laboratory payment methodology could pressure realized pricing and margins, while uncertainty may complicate contracting, forecasting, and investment decisions across the testing network.
Labcorp Holdings News
0JSY FAQ
What was Labcorp Holdings’s price range in the past 12 months?
Labcorp Holdings lowest share price was $245.87 and its highest was $326.00 in the past 12 months.
What is Labcorp Holdings’s market cap?
Labcorp Holdings’s market cap is $25.80B.
When is Labcorp Holdings’s upcoming earnings report date?
Labcorp Holdings’s upcoming earnings report date is Oct 22, 2026 which is in 65 days.
How were Labcorp Holdings’s earnings last quarter?
Labcorp Holdings released its earnings results on Jul 30, 2026. The company reported $4.99 earnings per share for the quarter, beating the consensus estimate of $4.779 by $0.211.
Is Labcorp Holdings overvalued?
According to Wall Street analysts Labcorp Holdings’s price is currently Undervalued.
Does Labcorp Holdings pay dividends?
Labcorp Holdings pays a Quarterly dividend of $0.72 which represents an annual dividend yield of 0.89%. See more information on Labcorp Holdings dividends here
What is Labcorp Holdings’s EPS estimate?
Labcorp Holdings’s EPS estimate is 4.65.
How many shares outstanding does Labcorp Holdings have?
Labcorp Holdings has 81,100,000 shares outstanding.
What happened to Labcorp Holdings’s price movement after its last earnings report?
Labcorp Holdings reported an EPS of $4.99 in its last earnings report, beating expectations of $4.779. Following the earnings report the stock price went up 0.399%.
Which hedge fund is a major shareholder of Labcorp Holdings?
Currently, no hedge funds are holding shares in GB:0JSY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Labcorp Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$338.27 (8.56% Upside)
$338.27 (8.56% Upside)
Blogger Sentiment
Neutral
GB:0JSY Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $722.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.03%
12-Months-Change
Fundamentals
Return on Equity
0.89%
Trailing 12-Months
Asset Growth
2.62%
Trailing 12-Months
Company Description
Labcorp Holdings
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
0JSY Company Deck
0JSY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operational and financial quarter: revenue growth, margin expansion, double-digit adjusted EPS growth, raised guidance, robust BLS backlog and book-to-bill, and multiple product/partnership launches. Headwinds highlighted were a meaningful quarter-over-quarter drop in free cash flow (timing and capex), a modest ACA-related volume headwind (~30 bps), prior and improving Early Development softness, higher patient-pay mix, and elevated absolute debt with relatively low cash on hand. On balance the positives around revenue, margins, guidance increases, product/market progress, and capital returns materially outweigh the cited challenges.View all GB:0JSY earnings summaries0JSY Revenue Breakdown
77.96% Dx
22.21% BLS
-0.16% Intercompany eliminations
0JSY Stock 12 Month Forecast
Average Price Target
$338.27
▲(8.56% Upside)